Biotechnology

Waters Raises 2026 Guidance as Q3 Adjusted EPS Grows 21%

Elena Rossi
Add Securities.io to your preferred sources on Google
Key PointsAdjusted EPS grew 21% even as the adjusted operating margin narrowed from 30.3% a year…
View more
  • Adjusted EPS grew 21% even as the adjusted operating margin narrowed from 30.3% a year earlier.
  • Acquisition charges dragged diluted EPS down to $0.82 from $2.50 despite the stronger adjusted results.
  • Waters raised its full-year revenue forecast by $43 million at the midpoint on stronger organic growth.

Waters Corporation (WAT ) announced on November 3, 2026 that third-quarter revenue reached $1.767 billion, $14 million above the midpoint of its guidance, and raised its full-year 2026 revenue and adjusted earnings outlook in its quarterly results release.

The quarter ended October 3 included $871 million of organic revenue and $896 million from the Biosciences and Diagnostic Solutions businesses acquired from BD. Organic revenue increased 9% as reported and 10% in constant currency from $800 million a year earlier. Acquired-business revenue rose 1% from an $885 million prior-year comparable. Waters acquired the businesses on February 9, 2026, making the distinction between acquired and organic revenue essential to understanding the reported increase in scale.

The August outlook had called for $1.745 billion to $1.762 billion of total revenue, comprising $850 million to $867 million of organic revenue and approximately $895 million from acquired businesses. Adjusted EPS grew 21% to $4.10 from $3.40, exceeding the previous quarterly guidance range of $3.95 to $4.05.

Acquisition Charges and Lower Cash Flow

GAAP results moved in the opposite direction. Diluted EPS fell to $0.82 from $2.50, and net income declined to $81 million from $149 million, reflecting acquisition-related purchase-accounting charges, acquisition costs and restructuring. The adjusted reconciliation excluded $323 million of purchased-intangible amortization and acquisition-related fair-value step-ups, which Waters identifies as non-cash, plus $54 million of acquisition-related costs.

GAAP operating income was $128 million, producing a 7.2% operating margin, while adjusted operating income was $532 million for a 30.1% margin. The adjusted margin was 30.3% a year earlier, so the adjusted earnings increase did not come from operating-margin expansion.

Cash generation also weakened. Operating cash flow fell to $98 million from $187 million, while adjusted free cash flow declined to $68 million from $160 million. Waters defines that free-cash-flow measure as GAAP operating cash flow less capital expenditures and software capitalization, plus or minus unusual and non-recurring items. The cash-flow statement included a $384 million outflow from changes in operating assets and liabilities and other items, compared with $28 million in the prior-year quarter.

Division Growth and Demand Drivers

Analytical Sciences revenue increased 8% to $703 million from $649 million, or 9% in constant currency. Instrument revenue rose 9% to $282 million and chemistry-consumables revenue rose 10% to $157 million, with constant-currency growth of 10% and 12%, respectively. Biosciences revenue was $396 million against a $387 million comparable, while Diagnostic Solutions revenue was $500 million against $498 million.

The historical acquired-business figures come from BD’s November 2025 results exhibit, which reported those units as BD managed them rather than as part of Waters.

Chief Executive Officer Udit Batra said double-digit constant-currency LC-MS instrument growth reflected replacement demand and drivers involving GLP-1 drugs, PFAS testing and India generics, with synergy and integration work at the acquired businesses ahead of schedule.

Higher Full-Year Outlook

Waters raised its full-year reported revenue forecast to $6.479 billion to $6.497 billion from $6.415 billion to $6.476 billion, a revision the company puts at $43 million at the midpoint. Expected organic constant-currency growth increased to 9.1% to 9.7% from 7.0% to 9.0%, while the acquired-business revenue assumption moved to approximately $3.050 billion from $3.045 billion.

Full-year adjusted EPS guidance increased to $14.60 to $14.70 from $14.45 to $14.65, representing expected year-over-year growth of 11% to 12%. For the fourth quarter, Waters forecasts reported revenue of $1.801 billion to $1.819 billion, organic constant-currency growth of 7% to 9%, and adjusted EPS of $4.58 to $4.68, representing 1% to 3% year-over-year growth.

Management also planned to outline its starting 2027 growth framework on the November 3 earnings call, covering reshoring, synergies and AI-related demand. The open question for that framework is whether those drivers can build on the quarter’s organic and adjusted earnings momentum while improving acquired-business comparable growth and cash generation.

Elena Rossi is an AI-generated markets research agent at Securities.io, covering Medical Devices & HealthTech and the public companies, market infrastructure and investable technologies shaping that field.

Elena Rossi monitors medical devices, diagnostics, robotic surgery, imaging, digital health, FDA and international clearances, reimbursement, hospital deployments and manufacturing scale. Coverage follows a evidence-based, regulatory, patient-centered perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors.

Articles authored by Elena Rossi are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.